Table 4: MBC Trials Conducted by the Translational Breast Cancer Research Consortium Trial # Status Trial Description Trial Presentations TBCRC 019 Closed to Accrual An Open Label, Randomized, Phase II Trial of AbraxaneTM (Paclitaxel Albumin-Bound Particles for Injectable Suspension), with or without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) (CS- 1008) in Patients with Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer 2013 SABCS Poster (Poster # P1-04-01); 2013 ASCO Poster (Abstract # 1052); 2011 ASCO Trials in Progress Poster (Abstract # TPS128) TBCRC 018 Closed to Accrual A Phase II Study of the PARP Inhibitor, Iniparib (BSI-201), in Combination with Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis 2014 Breast Cancer Research and Treatment Manuscript (PMID: 25001612 ); 2013 ASCO Poster Discussion Session (Abstract # 515); 2011 ASCO Trials in Progress Poster (Abstract # TPS127) TBCRC 015 Closed to Accrual Investigation of Genetic Determinants of Capecitabine Toxicity N/A TBCRC 013 Closed to Accrual A Prospective Analysis of Surgery in Patients Presenting with Stage IV Breast Cancer 2013 SABCS Poster (Poster # P2-18-09); 2013 ASCO Oral Presentation (Abstract # 507) TBCRC 011 Closed to Accrual Bicalutamide for the Treatment of Androgen Receptor Positive (AR(+)), Estrogen Receptor Negative, Progesterone Receptor Negative (ER(-)/PR(-)) Metastatic Breast Cancer Patients: A Phase II Feasibility Study 2013 Clinical Cancer Research Manuascript (PMID: 23965901); 2012 SABCS Poster (Poster # P6-05-02); 2012 ASCO Oral Presentation (Abstract # 1006); 2011 ASCO Trials in Progress Poster (Abstract # TPS122) TBCRC 010 Closed to Accrual Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis N/A TBCRC 009 Closed to Accrual A Phase II Study of Cisplatin or Carboplatin for Triple- Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response 2014 ASCO Oral Presentation (Abstract #1020); 2012 SABCS Poster Discussion Session (Poster Discussion # PD-09-03); 2012 Cancer Research Manuscript (PMID: 23135909 ); 2011 ASCO Poster Discussion Session (Abstract # 1025) TBCRC 007 Closed to Accrual MPA Revisited: A Phase II Study of Anti-Metastatic, Anti- Angiogenic Therapy in Postmenopausal Patients with Hormone Receptor Negative Breast Cancer. 2010 ASCO Poster (Abstract # 1074) TBCRC 003 Active A Phase 2 Study of Lapatinib in Combination with Trastuzumab in Patients with HER2-Positive, Metastatic Breast Cancer 2014 ASCO Poster Highlights Session (Abstract # 536); 2011 SABCS Poster (Poster # P2-09-07); 2011 2-ASCO Poster Discussion Sessions (Abstract # 527 & 528); 2010 ASCO Trials in Progress Poster (Abstract # TPS132) TBCRC 001 Closed to Accrual Phase II Trial of Cetuximab Alone and in Combination with Carboplatin in ER-Negative, PR-Negative, HER2- nonoverexpressing Metastatic Breast Cancers 2014ScienceSignaling Manuscript(PMID:24667376 ); 2012 JCO Manuscript (PMID: 22665533); 2009 SABCS Poster; 2008 Molecular Markers Poster (Abstract # 2); 2008 ASCO Oral Presentation (Abstract # 1009); 2007 SABCS Poster Discussion Session (Poster # 307) Abbreviations: ASCO American Society of Clinical Oncology, SABCS = San Antonio Breast Cancer Symposium